Renibus Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2016-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.renibus.com
An Evaluation of Patient Reported Outcomes and Clinical Outcomes
Recruiting
- Conditions
- Post-Operative Complications in Cardiac Surgery
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Renibus Therapeutics, Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT06092970
- Locations
- 🇨🇦
Research Site, Québec, Quebec, Canada
🇺🇸New York Presbyterian-Queens, Flushing, New York, United States
Effect of RBT-1 on Reducing the Risk of Post-Operative Complications in Subjects Undergoing Cardiac Surgery
Phase 3
Active, not recruiting
- Conditions
- Post-Operative Complications in Cardiac Surgery
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-09-01
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Renibus Therapeutics, Inc.
- Target Recruit Count
- 454
- Registration Number
- NCT06021457
- Locations
- 🇨🇦
Research Site, Québec, Quebec, Canada
Effect of RBT-1 on Preconditioning Response Biomarkers in Subjects Undergoing CABG and/or Cardiac Valve Surgery
Phase 2
Completed
- Conditions
- AKI
- Interventions
- Drug: High Dose RBT-1Drug: PlaceboDrug: Low Dose RBT-1
- First Posted Date
- 2020-09-25
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Renibus Therapeutics, Inc.
- Target Recruit Count
- 152
- Registration Number
- NCT04564833
- Locations
- 🇺🇸
Keck Hospital of USC, Los Angeles, California, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸McLaren Greater Lansing, Lansing, Michigan, United States
A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study)
Phase 2
Terminated
- Conditions
- COVID-19
- Interventions
- Drug: RBT-9 (90 mg)
- First Posted Date
- 2020-04-28
- Last Posted Date
- 2023-03-29
- Lead Sponsor
- Renibus Therapeutics, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT04364763
- Locations
- 🇺🇸
New Smyrna Beach, FL, New Smyrna Beach, Florida, United States
🇺🇸Berkley, MI, Berkley, Michigan, United States
🇺🇸El Paso, TX, El Paso, Texas, United States
A Study of RBT-3 in Healthy Volunteers and Volunteers With Stage 3/4 Chronic Kidney Disease
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Renibus Therapeutics, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT04072432
- Locations
- 🇺🇸
Riverside Clinical Research, Edgewater, Florida, United States
A Study of RBT-9 in Healthy Volunteers and Volunteers With Stage 3/4 Chronic Kidney Disease
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Renibus Therapeutics, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT04072861
- Locations
- 🇺🇸
Riverside Clinical Research, Edgewater, Florida, United States
A Study of RBT-1 in Healthy Volunteers and Subjects With Stage 3-4 Chronic Kidney Disease
- First Posted Date
- 2019-03-28
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Renibus Therapeutics, Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT03893799
- Locations
- 🇺🇸
Riverside Clinical Research, Edgewater, Florida, United States
RBT-1 Phase 1b Clinical Trial in Healthy Volunteers and Subjects With CKD
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2020-05-11
- Lead Sponsor
- Renibus Therapeutics, Inc.
- Registration Number
- NCT03630029
© Copyright 2025. All Rights Reserved by MedPath